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ABSTRACT 
Edelfosine is a synthetic alkyl ether phospholipid that represents a promising class of 
antitumor agents. However, analytical methods to measure these type compounds are 
scarce. The lack of a reliable methodology to quantify edelfosine is a major problem in 
ongoing and scheduled preclinical and clinical trials with this drug. We evaluated the 
applicability of high-performance liquid chromatography–mass spectrometry to determine 
edelfosine in biological samples and polymeric delivery systems. Sample pre-treatment 
involved polymer precipitation or cell lysis with methanol. HPLC separation was performed 
on an Alltima RP18 narrow-bore column and edelfosine quantification was done by 
electrospray ionization mass spectrometry (ESI-MS) using positive ion mode and selected 
ion monitoring. Assays were linear in the tested range of 0.3–10 µg/ml. The limit of 
quantification was 0.3 ng/sample in both matrices, namely biological samples and 
polymeric delivery systems. The interassay precision ranging from 0.79 to 1.49%, with 
relative errors of –6.7% and 12.8%. Mean extraction recovery was 95.6%.  
HPLC-ESI-MS is a reliable system for edelfosine analysis and quantification in samples 
from different sources, combining advantages of full automation (rapidity, ease of use, no 
need of extensive extraction procedures) with high analytical performance and throughput. 
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1. Introduction 
Synthetic alkyl ether phospholipids represent a promising class of antitum or agents that, 
unlike most conventional chemotherapeutic drugs, do not target the DNA but act at the 
level of the cell membrane [1-4]. The prototype of these antineoplastic ether phospholipids 
is ET-18-OCH3 (edelfosine, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) [1-4] 
that exerts a selective cytotoxic action against cancer cells [1, 5]. The antitumor effect of 
edelfosine is based mainly on two different mechanisms that can act synergistically 
against neoplastic growth. Edelfosine enhances the tumoricidal activity of macrophages [6] 
and exerts a direct cytotoxic effect on tumor cells through the induction of apoptosis [5, 7-
9]. This combination of a stimulatory effect on host defense cells and a direct destructive 
effect on neoplastic cells in one molecule makes edelfosine a potentially effective 
antitumor drug [4]. The antitumor activity of edelfosine is mostly due to its ability to induce 
apoptosis in tumor cells through a Fas/CD95 death receptor-mediated process [10, 11]. In 
addition, this ether lipid has been reported to inhibit tumor cell proliferation, metastasis and 
angiogenesis [4]. Encouraging data on purging leukaemic bone marrow prior to analogous 
bone marrow transplantation have been reported [12, 13].  
Although edelfosine has been shown to achieve remarkable in vitro effects against a 
variety of cancer cells, so far the in vivo antitumor effect has been rather modest. Several 
reports have documented the advantages of incorporating anticancer agents into drug 
delivery systems, such liposomes, micro– and nanoparticles, in order to improve 
therapeutic efficiency while markedly reducing non specific in vivo toxicity and to enhance 
antitumor efficacy [14]. A liposome-based formulation of edelfosine has been shown to be 
less hemolytic both in vitro and in vivo [15]. Nevertheless, liposomes are rapidly cleared 
from systemic circulation and are relatively quickly degraded in the body. Polymeric 
materials provide an alternative means for delivering chemotherapeutic agents, offering a 
number of advantages over liposome carriers. In this work, drug delivery systems (DDS) 
 3
loaded with edelfosine have been developed using biodegradable polymers (a copolymer 
of lactic and glycolic acid, PLGA) [16, 17]. These polymers have been used as surgical 
sutures or bone-connecting devices, have proven non-toxic and are approved by FDA for 
their parenteral use in humans.  
The remarkable antitumor properties of edelfosine have promoted ongoing and scheduled 
preclinical and clinical trials with this drug. These clinical studies require the availability for 
some biochemical probes in order to carry out toxicity, pharmacokinetics and 
pharmacodynamics studies with edelfosine. However, a major problem in pharmacokinetic 
studies lies in the lack of a reliable method for quantification of non-radiolabeled edelfosine 
in plasma and other organs. The quantification of edelfosine in cells and organs demands 
highly selective and sensitive analytical methods able to detect low drug concentration 
levels and to discriminate from the presence of metabolites and endogenous components. 
Conventional quantitative high-performance liquid chromatography (HPLC) assays with 
ultraviolet/fluorescence or electrochemical detection for edelfosine are not feasible due to 
the lack of chromophores and electroactive groups in the molecule. High-performance 
thin-layer chromatography with fluorescence detection has been evaluated for the 
quantification of ether phospholipids, but had several drawbacks such as lack of selectivity 
on silica gel surfaces and detection problems [18]. HPLC combined with light scattering 
detection was also investigated for edelfosine and its homologue ET-16-OCH3, which was 
used as the internal standard [19]. The retention and elution characteristics of both 
compounds were studied on silica, poly(ethylene glycol)-coated silica, reversed phase 
materials and polymeric resins. This method can only be used for studies of relatively high-
concentration edelfosine samples [19]. The possibility of using capillary gas 
chromatography for the analysis of edelfosine was also investigated [20, 21]. This 
technique appears to be very attractive because of its intrinsically high selectivity and 
sensitivity. Nevertheless, dephosphorylation is required and this reaction is far from being 
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quantitative [21]. Radioassays were also used for the measurement of edelfosine 
concentrations in pre-clinical studies. However, this technique is unsuitable for the specific 
determination of this cytostatic drug in clinical samples since it involves the use of 
radioactive-labelled edelfosine. Therefore, there is a great need for fast and sensitive 
analytical methods to support edelfosine clinical trials. 
During the last few years high-throughput techniques have emerged, including fast and 
automated sample handling as well as data analysis and interpretation. Liquid 
chromatography-tandem mass spectrometry is one of these efficient analysis tools. The 
addition of mass spectrometry to liquid chromatographic applications has dramatically 
improved the analysis of drugs and some endogenous compounds in biological samples. 
This technique provides low detection limits, reduced influence of interference and the 
possibility for shorter run times. Here, we describe a sensitive analytical method based on 
a highly specific and selective HPLC separation coupled to electrospray ionization mass 
spectrometry (ESI-MS). Two different applications of the developed method have been 
evaluated in this study: the quantification of edelfosine in polymeric DDS, as a quality 
control procedure of the manufacture of the formulation, and in uptake studies in cancer 
cells.  
 
2. Experimental 
2.1 Reagents 
Edelfosine (ET-18-OCH3) was from INKEYSA (Barcelona, Spain). Formic acid 99% was 
purchased from Aldrich (Barcelona, Spain). Methanol (HPLC grade) was obtained from 
Merck (Darmstadt, Germany). Ammonium acetate RPE-ACS was obtained from CARLO 
ERBA (Milan, Italy). 
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2.2 Instrumentation and chromatographic conditions 
The apparatus used for the HPLC analysis was a Model 1100 series LC coupled with an 
atmospheric pressure (AP)-electrospray ionization (ESI) mass spectrometer (HP 1100 with 
MSD VL, Waldbronn, Germany). Data acquisition and analysis were performed with a 
Hewlett-Packard computer using the ChemStation G2171 AA programe.  
Separation was carried out at 50 °C on a reversed-phase, 150 x 2.1 mm column packed 
with C18, 5 μm silica reversed-phase particles (Alltima®) obtained from Alltech (Sedriano, 
Milan, Italy). This column was preceded by a reversed-phase, C18, 5 μm guard column 
(kromasil®, 20x4 mm, Symta, Spain). The mobile phase was a mixture of methanol-1% 
formic acid (95:5, v/v). The aqueous solvent was filtered through a 0.45 μm HV filter 
(millipore) and degassed using a membrane degasser. Separation was achieved by 
isocratic solvent elution at a flow-rate of 0.5 ml/min. 
ESI-MS conditions were as follows: 
 6
 Ionization mode: ESI, positive 
Selected ion monitoring (SIM) 
Ions (m/z):  
Edelfosine 524.40 
Interface variables:  
Temperature 350 ºC 
Drying gas N2 (12 l/min) 
Nebulizer gas  N2 (30 p.s.i.; 1 p.s.i.=6894.76 Pa) 
Capillary voltage 4000 V 
Fragmentator voltage 140 V 
 
Optimization of the interface variables, such as gas flows and voltages was done manually 
during direct infusion of 10 μg/ml of the target analyte dissolved in methanol.  
2.3 Calibration standards 
A stock solution of edelfosine with a concentration of 100 µg/ml was prepared by 
dissolving 1 mg of edelfosine in 10 ml of methanol. Ten standard solutions of 0.3, 0.6, 1, 
1.2, 2, 2.5, 5, 6, 8 and 10 µg/ml of edelfosine were made by further dilution of the stock 
solution with appropriate volumes of methanol. The concentration range of edelfosine for 
the standard curve samples was between 0.3 and 10 µg/ml. 
The stock solutions of edelfosine were kept at 4ºC. 
2.4 Sample preparation 
For the analysis of edelfosine in DDS a known amount of particles was dissolved in 1 ml of 
chloroform. Then, 3 ml of methanol were added to precipitate the polymer. The samples 
were vortex-mixed for 1 min and centrifuged for 10 min at 9,400 g. A 500μl-aliquot of the 
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supernatants were transferred to limited volume autosampler vials capped and placed on 
the HPLC autosampler. A 1 μl-aliquot of the supernatant was injected onto HPLC column. 
The drug loading was expressed as μg of edelfosine per mg of DDS. 
Edelfosine was extracted from the cell samples by repeated freeze/thaw in liquid nitrogen. 
Then, 150 μl of methanol were added, samples were vortexed and centrifuged at 10000 g 
for 10 min at 4ºC (Biofuge Heraeus, Hanau, Germany). Blank cells samples were also 
extracted with methanol. A 1 μl-aliquot of the supernatant was injected onto HPLC column.  
2.5 Validation 
We applied an unweighted least-squares linear regression of the responses 
(chromatographic area of eldelfosine) as a function of the nominal concentrations for 
obtain the equation of each calibration curve. The parameters of each equation were used 
to compute back-calculated concentrations of calibrators and to obtain concentration 
values for that day´s quality-control samples and unknown samples.  
The method was validated by analysis of extracted cells samples without edelfosine. The 
selectivity of the assay was determined by the individual analysis of blank samples. The 
retention times of cell compounds in the matrix were compared with those of edelfosine. 
LOD was defined as the sample concentration resulting in a peak area of three times the 
noise level. LOQ was defined as the lowest drug concentration which can be determined 
with an accuracy and precision < 20%. In this work LOD of the assay method was 
determined by analysis of the peak baseline noise in ten blank samples. 
Three samples of each quality control pool and calibration samples were analyzed on 
three different days. On day 1 the number of samples of quality control was five. Precision 
and accuracy was determined. We assessed the within-day precision and the recoveries 
by performing replicate analyses of QC samples (1, 2 and 8 μg/ml). The procedure was 
repeated on different days with different samples of the same calibrators to determine 
between-day values. The mean recovery was calculated as (mean measured 
 8
concentration/theoretical concentration)x100. Imprecision of a method is expressed as the 
relative standard deviation (RSD) of the obtained values for each calibrator. Accuracy was 
measured according to the following equation: 
100×⎥⎦
⎤⎢⎣
⎡ −=
T
T
C
CXalueoretical ve from the differencPercentage  
Were X is the determined concentration of a quality control and CT is the theoretical 
concentration. To be acceptable, the measures should be lower than 15% at all 
concentrations. 
For ruggedness and robustness studies, a different phase columns such as Kromasil C18 
25 x 0.4 (Teknokroma, Spain), and Zorbax Stablebound (150x2.1 mm, Agilent, USA) were 
used. Similarly, the influences of mobile phase (percentage of methanol ranged from 90% 
to 99%) and column temperature (50ºC) on the analytical procedure were also evaluated. 
2.6 Application of the method 
This analytical HPLC method was applied to determine the edelfosine content in DDS and 
in human acute myeloid leukemia HL-60 cell line incubated with this cytostatic drug.  
Quality control of the formulations 
DDS loaded with edelfosine using biodegradable polymers were prepared. Drug loading 
was calculated from the ratio of the mass of drug in the particles to the mass of particles 
and expressed as μg of edelfosine per mg o DDS.  
Cell culture 
The human acute myeloid leukemia HL-60 cell line was grown in RPMI-1640 
supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 
units/ml penicillin, and 24 μg/ml gentamicin. Cells (1 x 106) were incubated with 3 and 5 
μg/ml edelfosine for 2 h at 37ºC in a humidified atmosphere of 5% CO2 and 95% air. After 
exhaustive washing (six times) with phosphate-buffered saline-2% bovine serum albumin to 
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eliminate loosely cell surface-bound ether lipid due to the strong binding of edelfosine to 
albumin, the drug uptake into the cells was determined. 
3. Results and discussion 
A HPLC-MS assay to allow the quantitation of eldelfosine levels in cells has been 
developed and validated. Before the 1990s, determination of drug uptake in cells usually 
required gas chromatographic and radioactive protocols. These traditional analytical 
methodologies were not amenable to high-throughput analysis because they are slow, 
costly, and suffer from poor selectivity. Moreover, both approaches required extensive 
sample preparation procedures and were time-consuming so that their application to 
clinical analysis is too difficult. The use of the tandem mass spectrometry-liquid 
chromatography to detect drugs and biomolecules in clinical chemistry has supposed an 
important breakthrough in clinical chemistry. Actually, the impact of liquid chromatography/ 
tandem mass spectrometry in the development of new clinical chemistry applications is 
considerable. Liquid-chromatography-mass spectrometry is specific, extremely rapid (the 
chromatographic process can occur in less than 5 min), has tremendous cycle samples 
(hundreds of samples can be analyzed sequentially, one after another without pause), and 
can achieve sensitivities in the picogram range. The electrospray ionization interface on 
the mass spectrometer is well suited to tolerate high eluent flow rates and “dirty” matrices. 
Moreover, in some cases, the enhanced selectivity and sensitivity provided by the 
quadrupole MS systems eliminate the need for extensive sample preparation procedures 
and, indeed, for chromatographic separation.  
3.1. Optimization of mass spectrometer 
The MS analysis of edelfosine was first investigated by direct introduction of the reference 
compound dissolved in a methanol-1% formic acid (95:5) mixture using electrospray 
interface in both positive and negative ion mode of ionization. The positive ion mode was 
chosen because greater signal-to-noise ratios were obtained when compared to negative 
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ion mode. The presence of a quaternary ammonium group in the molecule structure is 
responsible of the good MS response obtained with this ionization mode. The mass 
spectra of edelfosine are shown in Fig 1. It was recorded in full scan mode (m/z 100-600) 
Two main peaks were observed corresponding respectively to the [M+H]+, [M+Na]+, 
pseudomolecular ions that it is common to see when the electrospray ionization interface 
was employed (Fig. 1A). When a fragmentation voltage of around 30 V was applied other 
structurally significant fragmentation ion was observed (Fig. 1B). It is interesting to note 
that a characteristic product ion of m/z 487.32 was generated under these fragmentation 
conditions. This primary fragment resulted from the loss of the quaternary ammonium 
group (Fig. 2) and can be monitoring within the pseudomolecular ions [M+H]+ and [M+Na]+ 
for structural confirmation purposes. 
Parameters such as the capillary temperature and the capillary voltage, the fragmentation 
voltage as well as the desolvation gas flow were optimized in order to reach a maximum 
intensity for the fragment ions. In a first step the effect of fragmentator voltage on both the 
fragmentation pattern and the signal intensity of tested edelfosine was studied by varying 
the probe voltage between 0 and 280 V in full scan mode (m/z 100-600). Any significant 
effect was observed in the mass spectra of edelfosine. The pseudo-molecular ions [M+H]+ 
and [M+Na]+ and the main fragment of [(M+Na)-59]+ were stable even at higher 
fragmentator voltage. The high signal-to-noise ratios for the pseudo-molecular ions was 
achieved between 120 and 140 V as can be seen in Figure 3. Above this voltage a 
decrease of signal intensity of the pseudo-molecular ions [M+H]+ and [M+Na]+was 
observed for edelfosine, whereas the intensity of the main primary fragment of [(M+Na)-
59]+ was slightly increased to reach a fragmentator voltage of around 180 V.  
The effect of the capillary temperature on signal intensity was investigated by varying the 
temperature between 250ºC to 350ºC and keeping all other parameters constant. An 
improvement of the signal response could be achieved by increasing the capillary 
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temperature. The optimal value of temperature was found 350 ºC. No changes in 
fragmentation pattern of edelfosine could be observed over the applied temperature range. 
This fact indicates that the fragmentation is not the result of a thermal degradation. 
Sensitivity also was further improved by lowering the capillary voltage from 4.5 kV to 4 kV. 
For the quantitative measurements, the fragment ion with the highest signal response at 
fragmentation voltage of 140 (m/z 524.4) was selected for quantitative MS detection. We 
operated in the selected-ion monitoring (SIM) mode with an exact mass of m/z 524.4, a 
peakwidth of 0,25 min and a dwell time of 1000 msec. The use of the SIM detection mode 
assures better sensitivity and selectivity to this analysis. Increasing dwell time led to a loss 
in linearity without a significant increase in sensitivity. We added edelfosine to the matrices 
investigated and never detected interferences with MS detection. Therefore, the tedious 
and time-consuming sample clean-up procedures (solid-phase extraction, liquid-liquid 
extraction), performed when this drug is analyzed in biological samples using other 
techniques, can be avoided. We have also verified that under the chromatographic 
conditions described in the paper the baseline mass spectrum showed ions with lower m/z 
ratio (below m/z 275) after analysis of a plasma blank samples. Hence, as the selected 
mass fragment of edelfosine is the m/z 524 SIM ion, the developed method could be 
applied to the measure of edelfosine plasmatic concentrations.  
3.2. Optimization of chromatographic process 
To improve the sample throughput a column of 2.1 mm internal diameter with highly apolar 
eluent was used. The narrow bore of these columns led to a higher detector response than 
standard columns due to the decreased diffusion of the sample as it passes through the 
column. The packing selected (Alltima C18) was found to be durable and provided good 
retention behaviour at higher organic rates in mobile phase. This column is a polymerically 
bonded C18 reversed-phase narrow-bore column packed with double-encapped spherical 
modified silica gel particles synthesised from pure silica gel. The use of this column 
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enabled us to determine edelfosine in small sample volumes, because of silanol groups 
have been mostly end-capped and the residual metals have been completely removed. 
These silanols are highly acidic functional groups and are very reactive with the quaternary 
ammonium group of edelfosine. The effect of such secondary interaction on the 
chromatographic behaviour is clear. Edelfosine is eluted from non-deactivated columns as 
tailing and band-broadening chromatographic peaks, with insufficient chromatographic 
efficiency to measure this drug in cellular samples.  
Figure 4 and 5 show representative blank chromatograms and chromatograms obtained 
by analysis of edelfosine in cell extracts and in DDS, respectively. The retention time of 
edelfosine was of 2.5 min. Under the chromatographic conditions used the number of 
theoretical plates was near to 8500. We evaluated peak skew using the asymmetry 
coefficient As = b/a, where b is the distance after the peak maximum and a is the distance 
before the peak maximum, both a and b being measured at 10% of the total peak height. 
The asymmetry coefficients ranged between 1.12 and 1.27. No interfering peaks were 
visible in the chromatogram of cell extracts. On the other hand, a chromatographic peak 
with retention time of 0.7 min was observed when DDS were analyzed. Nevertheless, 
edelfosine exhibited a well-separated peak (α=4.9, Rs=4.9) under the chromatographic 
conditions described.  
3.3. Quantitative analysis 
Examination of linearity over the concentration range 0.3–10 μg/ml yielded a linear 
correlation of > 0.9996 from five separate assays. The relative standard deviation of the 
slope calculated with calibration curve data was 2.28%, indicating good repeatability 
(Table 1). For each calibration point, the concentrations were back-calculated from the 
equation of the linear regression curves. Linear regression of the back-calculated 
concentrations versus the nominal concentrations provided a unit slope and an intercept 
equal to 0 (Student t-test). The distribution of the residuals (difference between nominal 
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and back-calculated concentrations) showed random variations, the number of positive 
and negative values being approximately equal. The limit of detection for the assay was 
0.312 μg/ml (300 pg of edefosine). Compared with other methods for edelfosine 
quantification, this limit of detection was lower than those previously published (20 ng of 
edelfosine) [10]. The mean extraction efficiencies for edelfosine was 95.6 (4.5)% (n=9). 
The extraction efficiency was independent of concentration over the range studied. 
Measurement imprecision is shown in Table II. Precision studies showed RSD values 
ranging from 0.79 % to 1.49 % with relative errors of –6.7 and 12.8%.  
The reported method was used for the determination of the drug content in DDS. The drug 
content was 1.25 ± 0.07 μg of edelfosine per mg of particles with the polymer used in the 
formulation. These controlled delivery systems are promising systems for the delivery of 
anticancer drugs such as edelfosine. The method was also applied to the quantitation of 
edelfosine amount taken up by human acute myeloid leukemia HL-60 cells. As can be 
observed in Figure 6, about 38-47% of the edelfosine added to the culture medium is 
taken up by the leukemic cells. This amount of cell-incorporated ether lipid is enough to 
promote cell death in tumor cells as evidenced by subsequent triggering of apoptosis 
following 3-6 h of incubation under the same experimental conditions used for drug 
quantification (data not shown). Thus, the mass spectroscopy method reported here to 
determine edelfosine levels in biological systems gives more reliable, and accurate figures 
than other previous methods and therefore can be the best choice for drug measurement 
in future pharmacokinetic studies with this antitumor drug.   
4. Conclusion 
The experiments have demonstrated that HPLC with ESI (electrospray ionization) tandem 
mass spectrometric detection, together with the simplest extraction procedure, is a good 
alternative to other methods traditionally employed for the determination of edelfosine in 
biological fluids. The simplicity of the technique, the shorter analysis time and its high 
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sensitivity, together with the lack of need for using radiolabeled compounds, makes this 
technique particularly attractive for edelfosine pharmacokinetic studies. This methodology 
provides a useful and critical tool in the biomedical and clinical research of edelfosine. 
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